Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease

Chikamatsu, Mayuko; Watanabe, Hiroshi; Shintani, Yuhi; Murata, Ryota; Miyahisa, Masako; Nishinoiri, Ayano; Imafuku, Tadashi; Takano, Mei; Arimura, Nanaka; Yamada, Kotaro; Kamimura, Miya; Mukai, Baki; Satoh, Takao; Maeda, Hitoshi; Maruyama, Toru

doi:10.1016/j.jconrel.2023.01.039

Cited by 9 publications

(3 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonalcoholic fatty liver disease (NAFLD) is a major category of metabolic disorder [ 39 , 40 ] that presently impacts approximately a quarter of the global population, and the prevalence of NAFLD continues to increase as more people are affected by obesity [ 41 – 43 ]. FGF21 is considered a promising candidate for treating NAFLD [ 44 , 45 ]. FGF21 research remains in the early stage, and the safety and efficacy of FGF21 have been evaluated in many preclinical trials, but the necessary doses are high [ 46 – 48 ].…”

Section: Discussionmentioning

confidence: 99%

Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21

Liu,

Ning,

et al. 2024

Microb Cell Fact

View full text Add to dashboard Cite

Background Fibroblast growth factor 21 (FGF21) is a promising candidate for treating metabolic disorder diseases and has been used in phase II clinical trials. Currently, metabolic diseases are prevalent worldwide, underscoring the significant market potential of FGF21. Therefore, the production of FGF21 must be effectively improved to meet market demand. Results Herein, to investigate the impact of vectors and host cells on FGF21 expression, we successfully engineered strains that exhibit a high yield of FGF21. Surprisingly, the data revealed that vectors with various copy numbers significantly impact the expression of FGF21, and the results showed a 4.35-fold increase in expression levels. Furthermore, the performance of the double promoter and tandem gene expression construction design surpassed that of the conventional construction method, with a maximum difference of 2.67 times. Conclusion By exploring engineered vectors and host cells, we successfully achieved high-yield production of the FGF21 strain. This breakthrough lays a solid foundation for the future industrialization of FGF21. Additionally, FGF21 can be easily, quickly and efficiently expressed, providing a better tool and platform for the research and application of more recombinant proteins.

show abstract

Section: Discussionmentioning

confidence: 99%

Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21

Liu,

Ning,

et al. 2024

Microb Cell Fact

View full text Add to dashboard Cite

show abstract

“…After collecting the liver from the mouse, lipid extraction was performed following a previously reported methodology [ 24 ]. This sample was assayed for triglyceride and cholesterol using a Triglyceride E Test and Cholesterol E Test (FUJIFILM Wako Pure Chemical Industries, Ltd.), respectively.…”

Section: Methodsmentioning

confidence: 99%

“…H&E staining and Sirius red staining were performed as described in our previous study [ 24 ]. Liver sections were prepared with a thickness of 4 μm and observed using a BZ-X710 microscope Images with 10–14 fields collected for each mouse were randomly acquired and quantified.…”

Section: Methodsmentioning

confidence: 99%

Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis

Murata,

Watanabe,

Iwakiri

et al. 2024

Heliyon

Self Cite

View full text Add to dashboard Cite

Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation

Mao,

Guo,

Yang

et al. 2024

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease

Cited by 9 publications

References 63 publications

Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21

Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21

Albumin-fused thioredoxin ameliorates high-fat diet-induced non-alcoholic steatohepatitis

Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation

Contact Info

Product

Resources

About